Trends in Drug Discovery in Diabetes and Obesity

Lars Linderoth received a PhD in chemistry in 2008 from the Technical University of Denmark (DTU) working on enzyme triggered drug delivery with Professor Thomas Andresen, Professor Günther Peters and Professor Robert Madsen. In 2008 he joined Novo Nordisk, first as a 2-year post doc and later as a research scientist. Lars has been at Novo Nordisk since then, is now Director at Novo Nordisk and has managed various department within the area of research chemistry in Denmark. He has authored several publications and has been named as inventor on several patents within the field of drug discovery. Søren Østergaard received a PhD in chemistry in 1996 from The University of Copenhagen working on the design of peptide and peptidomimetic ligands for protein targets for the study of protein-protein interactions. After an assistant professorship he joined Novo Nordisk in 1997. Søren is currently a Principal Scientist with extensive experience in the field of peptide drug discovery, having authored more than 45 publications and is named as inventor on more than 20 patents.

• GENERAL ASPECTSDiabetes therapies overviewObesity therapies overview DRUG CLASSESGIP agonists/antagonists: Biological aspectsTrends within the field of insulinGLP1 receptor agonists; small molecules, peptidesNPY receptors as targets for diabetes and obesityAmylin and PrrPPoly-agonists for the treatment of diabetes and obesityEmerging targets: FGF21, MC4, leptin, ghrelin, leap2Oral antidiabetics beyond GLP1R agonists CASE STUDIESTirzepatideDasiglucagonTeplizumab